141 related articles for article (PubMed ID: 33143687)
1. Mapping EORTC QLQ-C30 and FACT-G onto EQ-5D-5L index for patients with cancer.
Hagiwara Y; Shiroiwa T; Taira N; Kawahara T; Konomura K; Noto S; Fukuda T; Shimozuma K
Health Qual Life Outcomes; 2020 Nov; 18(1):354. PubMed ID: 33143687
[TBL] [Abstract][Full Text] [Related]
2. Mapping the EORTC QLQ-C30 and QLQ H&N35 to the EQ-5D-5L and SF-6D for papillary thyroid carcinoma.
Huang D; Zeng D; Tang Y; Jiang L; Yang Q
Qual Life Res; 2024 Feb; 33(2):491-505. PubMed ID: 37938402
[TBL] [Abstract][Full Text] [Related]
3. Development of algorithms to estimate the EQ-5D-5L from the FACT-L in patients with lung cancer: a mapping study.
Jiang L; Zhou H; Yang Q; Luo X; Huang D
Qual Life Res; 2024 Mar; 33(3):805-816. PubMed ID: 38148367
[TBL] [Abstract][Full Text] [Related]
4. A non-linear beta-binomial regression model for mapping EORTC QLQ- C30 to the EQ-5D-3L in lung cancer patients: a comparison with existing approaches.
Khan I; Morris S
Health Qual Life Outcomes; 2014 Nov; 12():163. PubMed ID: 25388439
[TBL] [Abstract][Full Text] [Related]
5. Mapping the Minnesota living with heart failure questionnaire (MLHFQ) to EQ-5D-5L in patients with heart failure.
Kularatna S; Senanayake S; Chen G; Parsonage W
Health Qual Life Outcomes; 2020 Apr; 18(1):115. PubMed ID: 32349782
[TBL] [Abstract][Full Text] [Related]
6. The validation of published utility mapping algorithms: an example of EORTC QLQ-C30 and EQ-5D in non-small cell lung cancer.
Gregory J; Dyer M; Hoyle C; Mann H; Hatswell AJ
Health Econ Rev; 2020 Apr; 10(1):10. PubMed ID: 32319016
[TBL] [Abstract][Full Text] [Related]
7. Mapping Dermatology Life Quality Index (DLQI) scores to EQ-5D utility scores using data of patients with atopic dermatitis from the National Health and Wellness Study.
Vilsbøll AW; Kragh N; Hahn-Pedersen J; Jensen CE
Qual Life Res; 2020 Sep; 29(9):2529-2539. PubMed ID: 32297132
[TBL] [Abstract][Full Text] [Related]
8. A systematic review of patient-reported outcome measures for advanced skin cancer patients.
Reinhardt ME; Sun T; Pan CX; Schmults CD; Lee EH; Waldman AB
Arch Dermatol Res; 2023 Aug; 315(6):1473-1480. PubMed ID: 36469125
[TBL] [Abstract][Full Text] [Related]
9. Validation of the Japanese version of the EORTC hepatocellular carcinoma-specific quality of life questionnaire module (QLQ-HCC18).
Mikoshiba N; Tateishi R; Tanaka M; Sakai T; Blazeby JM; Kokudo N; Koike K; Kazuma K
Health Qual Life Outcomes; 2012 May; 10():58. PubMed ID: 22651810
[TBL] [Abstract][Full Text] [Related]
10. Assessment of outcome measures for cost-utility analysis in depression: mapping depression scales onto the EQ-5D-5L.
Gamst-Klaussen T; Lamu AN; Chen G; Olsen JA
BJPsych Open; 2018 Jul; 4(4):160-166. PubMed ID: 29897028
[TBL] [Abstract][Full Text] [Related]
11. Mapping the Oxford Shoulder Score onto the EQ-5D utility index.
Valsamis EM; Beard D; Carr A; Collins GS; Brealey S; Rangan A; Santos R; Corbacho B; Rees JL; Pinedo-Villanueva R
Qual Life Res; 2023 Feb; 32(2):507-518. PubMed ID: 36169788
[TBL] [Abstract][Full Text] [Related]
12. Condition-specific or generic preference-based measures in oncology? A comparison of the EORTC-8D and the EQ-5D-3L.
Lorgelly PK; Doble B; Rowen D; Brazier J;
Qual Life Res; 2017 May; 26(5):1163-1176. PubMed ID: 27830513
[TBL] [Abstract][Full Text] [Related]
13. EORTC QLQ-C30 general population normative data for the United States.
Rogge AA; Liegl G; Snyder C; Rose M; Nolte S;
Eur J Cancer; 2024 May; 202():114030. PubMed ID: 38552543
[TBL] [Abstract][Full Text] [Related]
14. Identifying changes in scores on the EORTC-QLQ-C30 representing a change in patients' supportive care needs.
Snyder CF; Blackford AL; Sussman J; Bainbridge D; Howell D; Seow HY; Carducci MA; Wu AW
Qual Life Res; 2015 May; 24(5):1207-16. PubMed ID: 25398495
[TBL] [Abstract][Full Text] [Related]
15. Responsiveness of EORTC QLQ-C30, QLQ-CR38 and FACT-C quality of life questionnaires in patients with colorectal cancer.
Uwer L; Rotonda C; Guillemin F; Miny J; Kaminsky MC; Mercier M; Tournier-Rangeard L; Leonard I; Montcuquet P; Rauch P; Conroy T
Health Qual Life Outcomes; 2011 Aug; 9():70. PubMed ID: 21859485
[TBL] [Abstract][Full Text] [Related]
16. Health-Related Quality of Life in Patients With Advanced Endometrial Cancer Treated With Lenvatinib Plus Pembrolizumab or Treatment of Physician's Choice.
Lorusso D; Colombo N; Herraez AC; Santin AD; Colomba E; Miller DS; Fujiwara K; Pignata S; Baron-Hay SE; Ray-Coquard IL; Shapira-Frommer R; Kim YM; McCormack M; Massaad R; Nguyen AM; Zhao Q; McKenzie J; Prabhu VS; Makker V
Eur J Cancer; 2023 Jun; 186():172-184. PubMed ID: 37086595
[TBL] [Abstract][Full Text] [Related]
17. Cross-walk of the Chronic Liver Disease Questionnaire for Nonalcoholic Steatohepatitis (CLDQ-NASH) and the EuroQol EQ-5D-5L in patients with NASH.
Fishman J; Higgins V; Piercy J; Pike J
Health Qual Life Outcomes; 2023 Oct; 21(1):113. PubMed ID: 37838660
[TBL] [Abstract][Full Text] [Related]
18. EORTC QLQ-C30 normative data for the United Kingdom: Results of a cross-sectional survey of the general population.
Young T; Velikova G; Liegl G; Rose M; Nolte S;
Eur J Cancer; 2024 Jun; 204():113927. PubMed ID: 38429166
[TBL] [Abstract][Full Text] [Related]
19. Deriving a preference-based measure for cancer using the EORTC QLQ-C30.
Rowen D; Brazier J; Young T; Gaugris S; Craig BM; King MT; Velikova G
Value Health; 2011; 14(5):721-31. PubMed ID: 21839411
[TBL] [Abstract][Full Text] [Related]
20. Obtaining EQ-5D-5L utilities from the disease specific quality of life Alzheimer's disease scale: development and results from a mapping study.
Rombach I; Iftikhar M; Jhuti GS; Gustavsson A; Lecomte P; Belger M; Handels R; Castro Sanchez AY; Kors J; Hopper L; Olde Rikkert M; Selbæk G; Stephan A; Sikkes SAM; Woods B; Gonçalves-Pereira M; Zanetti O; Ramakers IHGB; Verhey FRJ; Gallacher J; Actifcare Consortium ; LeARN Consortium ; Landeiro F; Gray AM;
Qual Life Res; 2021 Mar; 30(3):867-879. PubMed ID: 33068236
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
